TechNavio's analysts forecast the Global Non-small Cell Lung Cancer market to grow at a CAGR of 2.77 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Ophthalmic Drugs market has also been witnessing the trend of emergence of personalized medicines. However, the increasing use of complementary and alternative medicine could pose a challenge to the growth of this market. http://www.bharatbook.com/healthcare-market-research-reports/global-non-small-cell-lung-cancer-drugs-market-2012-2016.html
The Global Non-small Cell Lung Cancer Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-small Cell Lung Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating the Global Non-small Cell Lung Cancer market are AstraZeneca plc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., and Sanofi S.A.
The other vendors mentioned in the report are Bristol-Myers Squibb Co., GlaxoSmithKline Plc., Novartis AG, and OSI Pharmaceuticals Inc.
Key questions answered in this report:
What will the Global Non-small Cell Lung Cancer market size be in 2016 and what will the growth rate be?
What are the key trends in the Global Non-small Cell Lung Cancer market?
What is driving Global Non-small Cell Lung Cancer market?
What are the challenges to the growth in the Global Non-small Cell Lung Cancer market?
Who are the key vendors in the Global Non-small Cell Lung Cancer market?
What are the market opportunities and threats faced by the key vendors in the Global Non-small Cell Lung Cancer market?
What are the strengths and weaknesses of the key vendors?
Table of Contents
01. Executive Summary
03. Market Coverage
04. Market Landscape
Market Size and Forecast
04.1 Five Forces Analysis
05. Geographical Segmentation
06. Rate of Incidence and Prevalence
07. Vendor Landscape
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Key Vendor Analysis
14.1 F. Hoffmann-La Roche Ltd.
14.2 AstraZeneca plc
14.3 Eli Lilly and Co.
14.4 Sanofi S.A.
15. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Non-small Cell Lung Cancer Drugs Market 2012-2016 (US$ billion)
Exhibit 2: Global Non-small Cell Lung Cancer Drugs Market by Geographical Segmentation 2012
Exhibit 3: Global Non-small Cell Lung Cancer Drugs Market by Vendor Segmentation 2012
For more information kindly visit :
Global Non-small Cell Lung Cancer Drugs Market 2012-2016
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Follow us on twitter: https://twitter.com/researchbook
Our Blogs: http://www.linkedin.com/company/bharat-book-bureau
Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.